Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban-based versus antiplatelet-based antithrombotic strategy after TAVR
2015-001975-30Phase 3Terminated
- Sponsor
- Bayer
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban, aspirin and clopidogrel in aortic stenosis (AS) and thromboembolism (2 arms), sponsored by Bayer. Primary endpoint: Primary efficacy endpoint. Started Oct 2015; status: terminated.
02
Drugs
rivaroxabanaspirinclopidogrel
03
Conditions
aortic stenosis (AS)thromboembolism
Beyond the preview
Go deeper on 2015-001975-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001975-30.